CA Patent

CA2813049A1 — Modified compstatin with improved stability and binding properties

Assigned to University of Pennsylvania Penn · Expires 2012-03-29 · 14y expired

What this patent protects

Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These cyclic compounds are modified to improve stability while maintaining substantially equivalent complement activation-inhibitory activity as compared with currently…

USPTO Abstract

Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These cyclic compounds are modified to improve stability while maintaining substantially equivalent complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs in which the disulfide bond between C2 and C12 is modified via a thioether bond to form a cystathionine.

Drugs covered by this patent

Patent Metadata

Patent number
CA2813049A1
Jurisdiction
CA
Classification
—
Expires
2012-03-29
Drug substance claim
No
Drug product claim
No
Assignee
University of Pennsylvania Penn
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.